{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:17:59Z","timestamp":1790698679073,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.anai.2023.11.002","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T04:41:14Z","timestamp":1699591274000},"page":"383-389.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-9165","authenticated-orcid":false,"given":"Andrew F.","family":"Alexis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakiya P.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemal R.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz","family":"Fonacier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Rojo","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Levenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.anai.2023.11.002_bib0001","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","article-title":"Racial differences in atopic dermatitis","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.002_bib0002","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment","volume":"27","author":"Kaufman","year":"2018","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.002_bib0003","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2010.251","article-title":"Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health","volume":"131","author":"Shaw","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.anai.2023.11.002_bib0004","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.jid.2019.02.024","article-title":"Racial\/ethnic variation in use of ambulatory and emergency care for atopic dermatitis among US children","volume":"139","author":"Wan","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.002_bib0005","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaad.2022.09.054","article-title":"Racial and ethnic differences in barriers to care among US adults with chronic inflammatory skin diseases: A cross-sectional study of the All of US Research Program","volume":"88","author":"Nock","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.002_bib0006","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.002_bib0007","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jaci.2021.09.015","article-title":"Reframing racial and ethnic disparities in atopic dermatitis in Black and Latinx populations","volume":"148","author":"Croce","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.002_bib0008","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/jcm4050884","article-title":"Diagnosis of atopic dermatitis: mimics, overlaps, and complications","volume":"4","author":"Siegfried","year":"2015","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.anai.2023.11.002_bib0009","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jid.2018.10.029","article-title":"Racial\/ethnic differences in incidence and persistence of childhood atopic dermatitis","volume":"139","author":"Kim","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.002_bib0010","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1046\/j.1365-2133.2002.04965.x","article-title":"Reliance on erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts","volume":"147","author":"Ben-Gashir","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2023.11.002_bib0011","series-title":"Fitzpatrick's Dermatology in General Medicine","article-title":"Racial considerations: skin of color","author":"Reddy","year":"2012"},{"issue":"6","key":"10.1016\/j.anai.2023.11.002_bib0012","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jdv.18008","article-title":"Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics","volume":"36","author":"Bosma Al Ascott","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.anai.2023.11.002_bib0013","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamadermatol.2014.1674","article-title":"Efficacy of systemic treatments for atopic dermatitis in racial and ethnic minorities in the United States","volume":"150","author":"Bhattacharya","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.anai.2023.11.002_bib0014","unstructured":"Pfizer. Cibinqo 100-mg film-coated tablets. 2023. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/12873\/smpc#gref. Accessed October 26, 2023."},{"key":"10.1016\/j.anai.2023.11.002_bib0015","unstructured":"Pfizer. Japan\u2019s MHLW Approves Pfizer\u2019s Cibinqo\u00ae (Abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis. 2021. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/japans-mhlw-approves-pfizers-cibinqor-abrocitinib-adults. Accessed October 26, 2023."},{"key":"10.1016\/j.anai.2023.11.002_bib0016","unstructured":"Pfizer Labs. CibinqoTM (Abrocitinib) Tablets, for oral use. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213871s001lbl.pdf. Accessed October 26, 2023."},{"key":"10.1016\/j.anai.2023.11.002_bib0017","unstructured":"European Medicines Agency. Cibinqo\u00ae (abrocitinib). Summary of Product Characteristics. 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cibinqo-epar-product-information_en.pdf. Accessed October 26, 2023."},{"issue":"12","key":"10.1016\/j.anai.2023.11.002_bib0018","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2023.11.002_bib0019","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"10.1016\/j.anai.2023.11.002_bib0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2023.11.002_bib0021","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijwd.2015.05.002","article-title":"The reliability and validity of outcome measures for atopic dermatitis in patients with pigmented skin: a grey area","volume":"1","author":"Zhao","year":"2015","journal-title":"Int J Womens Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.002_bib0022","first-page":"1215","article-title":"Racial disparities in dermatology","volume":"315","author":"Narla","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.anai.2023.11.002_bib0023","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1525-1470.2012.01740.x","article-title":"Atopic dermatitis in African American children: addressing unmet needs of a common disease","volume":"29","author":"Vachiramon","year":"2012","journal-title":"Pediatr Dermatol"},{"issue":"7","key":"10.1016\/j.anai.2023.11.002_bib0024","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07434610902744074","article-title":"Objective assessment of psoriasis erythema for PASI scoring","volume":"33","author":"Ahmad Fadzil","year":"2009","journal-title":"J Med Eng Technol"},{"key":"10.1016\/j.anai.2023.11.002_bib0025","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Horeczko J, Alexis A. Development of an Eczema Area and Severity Index atlas for diverse skin types [e-pub ahead of print]. Dermatitis. https:\/\/doi.org\/10.1089\/derm.2023.0051, accessed October 10, 2023.","DOI":"10.1089\/derm.2023.0051"},{"issue":"1","key":"10.1016\/j.anai.2023.11.002_bib0026","doi-asserted-by":"crossref","first-page":"e014","DOI":"10.1097\/JW9.0000000000000014","article-title":"Art of prevention: atopic dermatitis in women and families of color-prevalence, recognition and prevention","volume":"8","author":"Wilson","year":"2022","journal-title":"Int J Womens Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.002_bib0027","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/jdv.15999","article-title":"Validation of the Patient-Oriented SCORing for Atopic Dermatitis tool for black skin","volume":"34","author":"Faye","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.anai.2023.11.002_bib0028","first-page":"S20","article-title":"Dermatological conditions in SKIN OF COLOR-: managing atopic dermatitis","volume":"14","author":"Sangha","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2023.11.002_bib0029","first-page":"804","article-title":"Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled Phase 3 trials","volume":"18","author":"Alexis","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.002_bib0030","first-page":"650","article-title":"Racial and ethnic disparities in access to emerging and frontline therapies in common dermatological conditions: A cross-sectional study","volume":"112","author":"Bell","year":"2020","journal-title":"J Natl Med Assoc"},{"issue":"2","key":"10.1016\/j.anai.2023.11.002_bib0031","first-page":"77","article-title":"Racial limitations of Fitzpatrick skin type","volume":"105","author":"Ware","year":"2020","journal-title":"Cutis"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623013947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623013947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:33:48Z","timestamp":1761053628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120623013947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1081120623013947"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2023.11.002","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2023.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}